SK&A broadens database coverage

Share this article:
Healthcare research firm SK&A has added new information and target data to its office-based physicians database, allowing clients a more precise understanding of a given practice.

The independently audited database maintains information on more than 638,340 US physicians, and will now provide secondary data such as whether or not a given practice accepts Medicare and Medicaid, for example. Additionally, the database will now provide information such as the number of exam rooms and office hours of each practice, whether a practice is accepting new patients and using electronic medical records, and what primary and secondary languages are used.

“The…insights gained from the response to these new survey questions will enable more sophisticated analysis and targeting of every physician and physician office in the US,” said Dave Escalante, president and CEO at SK&A, in a statement.

SK&A's database already includes physician information such as contact information, NPI, DEA and UPIN numbers, prescribing volume, participation in clinical trials and availability to see sales reps.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?